China Resources Sanjiu Medical & Pharma (000999) Earnings: 1Q Net Income Hits 1.27 Billion Yuan

China Resources Sanjiu Medical & Pharma on Smartkarma

Analyst coverage of China Resources Sanjiu Medical & Pharma on Smartkarma reveals key insights from Xinyao (Criss) Wang. In the report “China Healthcare Weekly (Feb.16),” it is highlighted that China’s biotech industry may have sold core assets prematurely, missing out on future gains. The impact of US tariffs on the industry is noted, with short-term challenges expected to pave the way for long-term upgrades. The imminent acquisition of Tasly by CR Sanjiu is progressing rapidly post-Spring Festival, anticipating completion in Q1 2025 after receiving necessary approvals.

Xinyao (Criss) Wang, in another report “China Healthcare Weekly (Feb.2),” emphasizes the need for Chinese biotech firms to innovate new blockbuster products for sustained growth. The ongoing acquisition of Tasly by CR Sanjiu is highlighted, with the necessity for product sales to rise continually to offset costs and maintain profits. The report notes a potential decline in biotech companies in the market as a supply side reform, favoring top-tier companies. The completion of the Tasly acquisition may extend to H1 2025 if approval timelines are extended.

A look at China Resources Sanjiu Medical & Pharma Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is positioned for a positive long-term trajectory based on the Smartkarma Smart Scores. The company excels in dividend payouts and growth potential, scoring high marks of 5 and 4 respectively. With a solid resilience score of 4, China Resources Sanjiu Medical & Pharma demonstrates the ability to withstand market fluctuations. However, there is room for improvement in the value and momentum scores, both rated at 3.

China Resources Sanjiu Medical & Pharma focuses on manufacturing and marketing medicines, healthcare products, and medical instruments. Additionally, the company is involved in pharmaceutical trading, printing, food manufacturing, real estate development, and provision of medical services. With an overall positive outlook and strengths in dividend yield, growth prospects, and resilience, China Resources Sanjiu Medical & Pharma appears well-positioned for sustained success in the competitive medical and pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma